https://doi.org/10.4081/aiua.2018.1.44

Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors

Vol. 90 No. 1 (2018)
Submitted: December 29, 2017
Accepted: February 20, 2018
Published: March 31, 2018
Erectile dysfunction, Psychotropic drugs, Phosphodiesterase 5-inhibitors, Antipsychotic drugs, Antidepressant drugs, Benzodiazepines
Abstract Views: 2212
PDF: 1382
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Rossella Mazzilli
rossella.mazzilli@uniroma1.it
Andrology Unit, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Gloria Angeletti
NESMOS (Neurosciences, Mental Health, and Sensory Organs) Department, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Soraya Olana
Andrology Unit, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Michele Delfino
Andrology Unit, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Virginia Zamponi
Andrology Unit, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Chiara Rapinesi
NESMOS (Neurosciences, Mental Health, and Sensory Organs) Department, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Antonio Del Casale
NESMOS (Neurosciences, Mental Health, and Sensory Organs) Department, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, .
Georgios D. Kotzalidis
NESMOS (Neurosciences, Mental Health, and Sensory Organs) Department, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Jlenia Elia
Andrology Unit, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Gemma Callovini
NESMOS (Neurosciences, Mental Health, and Sensory Organs) Department, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Paolo Girardi
NESMOS (Neurosciences, Mental Health, and Sensory Organs) Department, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Fernando Mazzilli
Andrology Unit, Sant’Andrea Hospital, Sapienza University of Rome, School of Medicine and Psychology, Rome, Italy.
Objectives: The aim of this study was to assess the prevalence of patients with Erectile Dysfunction (ED) receiving psychotropic drugs, the impact of these drugs on hormonal profile, and the efficacy of PDE5-i in these patients.
Materials and methods: We recruited 1872 patients referring for ED to our Andrology Unit. Assessment included serum testosterone, gonadotropins, TSH, prolactin, and PSA, and the IIEF-5 questionnaire for ED diagnosis. Inclusion criteria were age 21-75 years and IIEF-5 total score ≤ 21; exclusion criteria included hypogonadism, diabetes mellitus, previous prostatectomy, other medication intake, and ED diagnosis prior to psychotropic drug treatment. Efficacy was rated with the IIEF-5 (remission: total score ≥ 22).
Results: The prevalence of ED patients treated with psychotropic drugs since ≥ 3 months was 9.5% (178/1872), subdivided according to the drugs used into: Group A, 16 patients treated with atypical antipsychotics (9.0%); Group B, 55 patients with benzodiazepines (30.9%); Group C, 33 patients with antidepressant drugs (18.5%); and Group D, 74 patients with multiple psychotropic drugs (41.6%). Patients in Group A were significantly younger than other groups (p < 0.05). The hormonal profile presented only higher prolactin level in patients treated with antipsychotics, alone or in combination (p < 0.05). Overall, 146 patients received PDE5-i. Remission rate, after three months of treatment, was significantly higher in Group B compared to C and D groups (p < 0.05).
Conclusions: A substantial portion of patients receiving psychotropic drugs show ED. Sexual performance in these patients benefits from PDE5-i. Age, effects of psychiatric disorders, psychotropic drugs, and PDE5-i treatment modality accounted for variability of response in this sample.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Mazzilli, R., Angeletti, G., Olana, S., Delfino, M., Zamponi, V., Rapinesi, C., Del Casale, A., Kotzalidis, G. D., Elia, J., Callovini, G., Girardi, P., & Mazzilli, F. (2018). Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors. Archivio Italiano Di Urologia E Andrologia, 90(1), 44–48. https://doi.org/10.4081/aiua.2018.1.44

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.